LightBridge

Future of Diagnosing and Evaluating Alzheimer's Disease

The Future of Diagnosing and Evaluating Alzheimer's Disease

Different forms of dementia have different pathologies (causes, processes, development, and consequences) and respond to different medications. Even within one type of dementia, there may be differences in pathologies that make one subtype more responsive to certain treatments than another. Correctly diagnosing the type of dementia and identifying individual differences in disease expression are very important for improving dementia care and refining treatment regimens to each individual. Additionally, it is important to detect dementia early in the disease process when symptoms are mild or not yet evident, with the hope of delaying or preventing disease progression. So how does one detect a disease before symptoms develop?

Advances in the detection of biomarkers (characteristics that can be measured and evaluated as indicators of biologic or disease processes or responses to treatment) can help with the early diagnosis and characterization of dementias.

Currently, the diagnosis of Alzheimer's disease (AD) is often nonspecific and labored, as other disease processes need to be excluded before a diagnosis can be made. Even then, a specific diagnosis cannot always be made with confidence. Part of the problem is that few biomarkers are currently available for the evaluation of dementias. In addition, current brain imaging techniques are often underutilized. Lastly, the traditional criteria for diagnosis is outdated and do not incorporate newer biological characteristics of AD.

Diagnosing Alzheimer's Disease

Scientists and physicians have recently proposed a new set of criteria for the diagnosis of (AD) that includes two core criteria.

Proposed new criteria for Alzheimer's disease diagnosis

The first part of the criteria, episodic memory impairment, is similar to current diagnostic criteria and practice. The key to the new criteria is the incorporation of biological data identified through brain imaging, blood or CSF tests, or genetic testing.

Brain Imaging

Brain imaging can be used to 1) diagnosis dementia, 2) measure disease progression, and 3) evaluate for disease risk. There are two kinds of brain imaging: structural and functional.

• Structural imaging provides information about the brain anatomy and can detect loss of brain cells, tumors, strokes, certain brain infections, damage from head trauma, large blood clots, or abnormal fluid collections. Structural techniques include magnetic resonance imaging (MRI) and computed tomography (CT).

MRI is typically part of the standard evaluation for AD, because AD is associated with brain cell damage and atrophy (shrinkage) in specific regions of the brain, including the medial temporal lobe (an area important for memory). MRI is also useful in the evaluation of "mild cognitive impairment" (MCI), as studies have shown that individuals with MCI and medial temporal lobe shrinkage progress to AD more rapidly than those without medial temporal lobe shrinkage.

• Functional imaging reflects the metabolism or level of activity in different brain regions by showing how actively the cells use sugar or oxygen. Functional techniques include functional MRI (fMRI) and molecular neuroimaging, which include positron emission tomography (PET), and single photon emission computed tomography (SPECT). Medicare will pay for a PET scan to help distinguish Alzheimer's from frontotemporal dementia.

FDG-PET is a type of PET imaging that measures glucose metabolism in the brain. In AD, there is hypometabolism, or decreased activity, in specific regions of the brain, particularly the temporoparietal and posterior cingulate cortices. This pattern of reduced metabolism helps distinguish AD from frontotemporal dementia. FDG-PET can also be used to evaluate MCI, which, on average, shows a milder, AD-type pattern of low metabolism. Additionally, FDG-PET is a good way to detect individual differences in disease expression, which can help tailor treatments to the individual.

PIB-PET is a type of PET imaging that shows brain amyloid deposits using the imaging agent, 11C-PIB (Pittsburgh Compound B). The brain of someone with AD usually demonstrates increased PIB binding (or higher levels of amyloid) compared to normal brains.

There is ongoing research to develop better amyloid imaging agents, some of which are currently in clinical trials. The goal is to find agents that are more sensitive and specific to amyloid, more stable, and have few side-effects.

Using a combination of these imaging techniques can help distinguish different types of dementias and allow earlier detection of AD. In the future, brain imaging will play a greater role in dementia care.

Easily Accessible Biomarkers

Another way to detect AD and monitor its course is through biomarkers that are relatively easy to collect and test, such as biomarkers in blood or cerebral spinal fluid (CSF). Currently, a brain biopsy to test for the biomarkers of neurofibrillary tangles and amyloid plaques is the only definitive test for AD. Brain biopsies are challenging procedures that, if desired, are typically done after a person has died. Therefore there is ongoing research on more easily accessible biomarkers in the following areas.

• Cerebral Spinal Fluid (CSF): Currently there is no established test for AD using CSF, however, studies that have shown distinct patterns of biomarkers in the CSF of those with AD and MCI. For example, the CSF of those with AD and MCI shows reduced levels of a protein called Ab42 and elevated levels of proteins T-tau, P-tau, and beta-secretase (BACE1). Another group has identified a panel of 23 proteins in CSF that could be used as possible biomarkers for AD with 93% sensitivity. CSF tests should become commercially available in the near future. The disadvantage of testing for CSF biomarkers is that collecting CSF requires a trained physician, and the procedure can be risky and uncomfortable.
• Blood: Although blood tests for AD biomarkers are not currently available, several promising studies have identified proteins in the blood of individuals with AD that are present in abnormal levels. One research group is working to develop a test measuring a combination of 18 proteins that appears to diagnose AD with 90% accuracy. Another test measures levels of one protein found on white blood cells, CD-69. The advantage of blood tests is that blood is relatively safe and easy to collect. A blood test for AD may be available in late 2008.
• Genetic Markers: Although many genes have been found to determine susceptibility to older onset AD, the most important gene appears to be the E4 isoform of apolipoprotein E (ApoE4). Having the ApoE4 gene increases the risk and decreases the age of onset for the disease. Therefore those with the ApoE4 gene may need early, specialized treatment for AD. It is important to keep in mind that having the ApoE4 gene does not necessarily lead to disease development, as numerous risk factors are involved.

Currently there are three known autosomal dominant genetic syndromes that cause early onset AD. The mutations are found in the APP, PS1, and PS2 genes. This means that if a parent has a mutation in one of these genes, then the child has a 50% chance of inheriting the disease. These three genes only account for about half of the inheritable, early onset form of AD, which indicates that additional genes associated with inheritable forms of AD have yet to be identified. It is important to remember that most cases (approximately 95%) of AD are not associated with mutations in these three genes.

With the development and expanded use of biomarkers and brain imaging techniques, there is hope for improving Alzheimer's care. Earlier, more accurate diagnosis will allow for earlier and better treatment decisions that may slow or prevent disease onset and progression. It will allow easier monitoring of the disease and response to treatments. Lastly, treatments can be personalized to the individual for best response.

This information is not meant to be a substitute for medical advice, read more at: http://www.lightbridgehealthcare.com/lega.xml

To learn about LightBridge products, please visit: http://www.lightbridgehealthcare.com/products/cdroms.xml

®2007 LightBridge Healthcare Research, Inc.
www.LightBridgeHealthcare.com

References:

Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007;11:1227-38.
Cummings JL. Summary: practical implications for health care professionals. Presented at the International Conference on Alzheimer's Disease (ICAD); Chicago. July 29, 2008.
De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med. 2004;256:205-23.
Dubois B, Feldman HH, Jacova C, Dekosky ST, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-46.
Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol. 2006;61:120-9.
Foster NL. Promises from the brain: AD advances in neuroimaging. Presented at the International Conference on Alzheimer's Disease (ICAD); Chicago. July 29, 2008.
Hampel H, Burger K, Teipel SJ, Bokde Al, et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38-48.
Klunk WE, Engler H, Nordberg A, Wang Y, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19.
Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94-100.
Neale T. ICAD: biomarkers may help identify pre-clinical Alzheimer's. Medpage Today. http://www.medpagetoday.com/MeetingCoverage/ICAD/tb/10323. Retrieved August 1, 2008.
Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol. 2004;3:519-27.
Ono M. Molecular imaging of beta-amyloid plaques in the brain. Brain Nerve. 2007;59:233-40.
Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359-62.
Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1:13-21.
Schindowski K, Eckert A, Peters J, Gorriz C, et al. Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy. Neuromolecular Med. 2007;9:340-54.
Sunderland T, Linker G, Mirza N, Putnam KT, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA. 2003;289:2094-103.
Van de Pol LA, van der Flier WM, Korf ES, Fox NC, et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology. 2007;69:1491-7.
Visser PJ, Verhey F, Hampel H, Barger K, et al. Cerebrospinal fluid markers of Alzheimer's disease in subjects with subjective complaints and mild cognitive impairment. Presented at the International Conference on Alzheimer's Disease (ICAD); Chicago. July 30, 2008.
Waldemar G, Dubois B, Emre M, Georges J, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1-e26.
Wang Y, Klunk WE, Debnath ML, Huang GF, et al. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci. 2004;24:55-62.
Zhong Z, Ewers M, Teipel S, Burger K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007;64:718-26.